Research: Leverage Proprietary Ingredients for GLP-1 Demographic
Leveraging Proprietary Ingredients for the GLP-1 Demographic
The rapid proliferation of glp-1-medications has created a distinct consumer demographic with specific metabolic and gastrointestinal needs. Because these medications significantly alter gut motility and hormone signaling, food, beverage, and ingredient manufacturers are leveraging proprietary prebiotics, probiotics, and postbiotics to address side effects and support the gut-brain axis [3, 12]. Additionally, functional beverage brands are positioning proprietary ingredient stacks to naturally stimulate endogenous GLP-1 secretion, aiming to capture consumers shifting away from traditional carbonated-soft-drinks-csd [11].
The GLP-1 Microbiome Disruption
glp-1-medications function by mimicking hormones that manage blood glucose levels, appetite, and digestion, which inherently slows gastric emptying [12]. This disruption to the digestive system often leads to gastrointestinal side effects such as nausea, bloating, constipation, and diarrhea [12]. Furthermore, the medication can disrupt the balance of the gut microbiome.
To counteract this, consumers are increasingly seeking out functional products containing biotics that restore microbial balance and improve gut motility [12]. Industry experts note that the excessive use of pharmaceutical drugs, including GLP-1s, means that a standard healthy diet is often no longer sufficient to maintain gut health, driving demand for advanced functional-premiumization in food and supplements [3].
Proprietary Postbiotics: The Case of L. gasseri CP2305
To target the gut-brain axis in stressed demographics—including those impacted by the physiological changes of GLP-1 medications—major conglomerates are commercializing highly researched proprietary strains. A primary example is lactobacillus-gasseri-cp2305, a postbiotic strain developed by asahi-group-holdings through its subsidiary asahi-group-foods [6, 7].
Initially discovered through Asahi’s extensive research into Calpis-derived lactic acid bacteria [7], CP2305 has been shown in human clinical trials to reduce anxiety, improve sleep quality, and modulate the gut microbiome by maintaining beneficial Bifidobacterium levels [1, 4].
To scale this ingredient globally, Asahi entered a strategic distribution agreement with adm-wild-valencia (ADM) [2, 7]. ADM is positioning the ingredient for better-for-you snacks, functional beverages, and supplements, explicitly noting its relevance as consumers draw tighter correlations between gut health and mental well-being in the age of GLP-1s [2, 3]. Because CP2305 is a heat-inactivated postbiotic, it can withstand harsh formulation environments like high-heat processing and high-water content, making it highly viable for the adult-soft-drinks category [7].
Prebiotic Sodas and Endogenous GLP-1 Secretion
While postbiotics are being used to manage the secondary effects of GLP-1 medications, prebiotic functional sodas are being investigated for their ability to naturally stimulate the body’s own GLP-1 secretion.
A clinical trial (NCT07105826) conducted by Texas Christian University has been designed to evaluate the acute effects of popular prebiotic sodas—specifically olipop and poppi—against traditional caloric and non-caloric sodas like coca-cola and Diet Coke [11, 13].
- The Hypothesis: Prebiotic beverages enhance satiety and GLP-1 secretion due to their high fiber content, which ferments via the gut microbiota to produce short-chain fatty acids (SCFAs), without causing the significant glucose or insulin spikes associated with traditional CSDs [11, 14].
- Market Impact: If clinically substantiated, this mechanism offers a physiological explanation for the-diet-soda-paradox, wherein consumers utilizing GLP-1 medications are actively abandoning artificial calorie-free sodas in favor of functional prebiotic alternatives that actively support their metabolic goals.
Recombinant Delivery Systems for GLP-1
Beyond natural stimulation and symptom management, proprietary bacterial strains are being actively researched as direct delivery vehicles for GLP-1 peptides. Recent studies have successfully engineered recombinant Lactobacillus gasseri (LgsGPA) to orally deliver GLP-1 peptides [5]. In animal models for Type 2 diabetes, this bioengineered strain modulated the gut microbiota by reducing harmful bacterial taxa (such as Erysipelotrichaceae) and directly contributed to therapeutic metabolic regulation [5]. While this remains in the pharmaceutical realm, it highlights the convergence of proprietary biotics and GLP-1 therapies.
Contradictions and Challenges
The Fermentation Paradox
There is a notable contradiction in the use of prebiotic sodas to manage GLP-1 side effects. While prebiotics feed beneficial gut microbes to produce beneficial SCFAs, a natural byproduct of this fermentation process is gas [14, 15]. Consequently, prebiotic sodas can cause digestive distress, including severe bloating and changes in bowel movements, particularly if the consumer experiences a rapid increase in fiber intake [14, 15]. Because GLP-1 medications already cause nausea and bloating due to slowed gastric emptying [12], introducing high-fiber prebiotics could temporarily exacerbate the exact gastrointestinal discomfort the consumer is trying to resolve.
Regulatory Substantiation
Brands utilizing proprietary ingredients to target the GLP-1 demographic must navigate strict regulatory frameworks. ADM notes that any claims regarding ingredient traits must adhere to the scientific and legislative standards of the final product’s market [1]. The marketing of these products skirts the line of fda regulations, and brands must ensure they possess competent-and-reliable-scientific-evidence to avoid enforcement actions related to unapproved drug claims.
Further Research Directives
To build a more comprehensive understanding of this trend, future research should investigate:
- Longitudinal Cannibalization Data: Point-of-sale or basket-level-scanner-data tracking the exact drop in traditional CSD purchases among verified GLP-1 users transitioning to prebiotic sodas.
- Corporate R&D Initiatives: How innovation hubs like asahi-quality-and-innovations-aqi are utilizing backcasting methodologies to develop the next generation of postbiotics specifically tailored to the GLP-1 weight-loss demographic.
- Clinical Trial Outcomes: The published results of the TCU trial (NCT07105826) to see if brands like Olipop can definitively claim endogenous GLP-1 stimulation.
References
- [PDF] A Cutting Edge Solution - ADM — adm.com
- Boosting gut and brain health with a single ingredient — foodnavigator-usa.com
- Postbiotic L. gasseri CP2305 for stress, mood, sleep, women’s health — nutraingredients.com
- Health Benefits of Lactobacillus gasseri CP2305 Tablets in Young Adults Exposed to Chronic Stress: A Randomized, Double-Blind, Placebo-Controlled Study — mdpi.com
- Oral delivery of GLP-1 peptide using recombinant Lactobacillus gasseri for the treatment of type 2 diabetes mellitus - PMC — pmc.ncbi.nlm.nih.gov
- Our Business｜Asahi Group Foods — asahi-gf.co.jp
- ADM and Asahi Group Sign Exclusive Distribution Agreement for Innovative Postbiotic Designed to Support Stress, Mood and Sleep | ADM — adm.com
- Materials Discovery | R&D | ASAHI GROUP HOLDINGS — asahigroup-holdings.com
- Asahi’s health business, Gencor’s GLP-1 study and more in Jun’s most-read stories — nutraingredients.com
- Reducing Sugar and Together Building Better Health for People Everywhere | Planet Positivity in Action | OUR STORIES | ASAHI GROUP HOLDINGS — asahigroup-holdings.com
- Study Details | NCT07105826 | Impact of Prebiotic Sodas on Satiety and Metabolic Responses in Healthy Men | ClinicalTrials.gov — clinicaltrials.gov
- Do Prebiotics and Probiotics Help with GLP-1 Side Effects? - Fleet — fleetlabs.com
- Impact of Prebiotic Sodas on Satiety and Metabolic Respon… — clinicaltrial.be
- Prebiotic Soda Side Effects: What You Need to Know Before Drinking – wildwonder — drinkwildwonder.com
- Prebiotic Soda Side Effects: What You Need to Know Before Drinking – wildwonder — drinkwildwonder.com